Can-Fite(CANF)

Search documents
Can-Fite(CANF) - 2020 Q2 - Earnings Call Transcript
2020-08-28 01:51
Can-Fite BioPharma Ltd. (NYSE:CANF) Q2 2020 Earnings Conference Call August 27, 2020 4:15 PM ET Company Participants Pnina Fishman - Chief Executive Officer Motti Farbstein - Chief Financial Officer Conference Call Participants Jason Kolbert - Dawson James Vernon Bernardino - H.C. Wainwright & Co., LLC Operator Good afternoon, everyone, and thank you for joining Can-Fite's Second Quarter 2020 Conference Call. Today, the Company will provide a financial update for the quarter ended June 30, 2020, as well as ...
Can-Fite BioPharma (CANF) Investor Presentation - Slideshow
2020-06-09 21:58
Can-Fite Presentation June 2020 (NYSE American: CANF) (TASE:CFBI) (NYSE American: CANF) (TASE:CFBI) Forward Looking Statement • This presentation contains forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are "forward looking statements". • Forward-look ...
Can-Fite(CANF) - 2020 Q1 - Earnings Call Transcript
2020-06-01 18:15
Can-Fite BioPharma Ltd. (NYSE:CANF) Q1 2020 Results Conference Call June 1, 2020 8:30 AM ET Company Participants Bob Yedid - LifeSci Advisors Pnina Fishman - CEO Motti Farbstein - CFO Conference Call Participants Jason Kolbert - Dawson James Vernon Bernardino - H.C. Wainwright Operator Greetings and welcome to the Can-Fite BioPharma First Quarter 2020 Business Update Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presenta ...
Can-Fite(CANF) - 2019 Q4 - Annual Report
2020-03-27 20:26
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 00 ...
Can-Fite(CANF) - 2018 Q4 - Annual Report
2019-03-29 20:28
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 00 ...
Can-Fite BioPharma (CANF) Presents At Biotech Showcase Investor Conference - Slideshow
2019-01-10 20:25
Can-Fite Presentation Pnina Fishman, CEO Motti Farbstein, CFO November 2018 (NYSE American: CANF) (TASE:CFBI) (NYSE American: CANF) (TASE:CFBI) Forward Looking Statement • This presentation contains forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are ...